Archive
1250 articles, sorted by publication time.
An all-stock transaction combined with a large private placement gives cash-strapped Jasper access to Kira’s complement and B-cell drug candidates; however, existing shareholders face substantial dilution, and the new clinical narrative still needs to be validated by data in kidney disease, PNH, and rare diseases.
From real-time prompts providing the basis for diagnosis and treatment during medical-record conversations to literature-based answers for physicians’ queries, specialized clinical AI systems are competing to become the gateway to decision-making. Yet usage rates, internal safety scores, and actual improvements in patient outcomes remain three different things.
The University of Oxford spinout has moved into a new 5,500-square-foot facility as it prepares to advance its ovarian cancer candidate and follow-on solid tumor programs; however, the publicly available evidence remains primarily preclinical, and efficacy in humans has yet to be determined in trials.
Diranersen reduced Tau pathology in the brain in a Phase 2 trial and showed signals of slowing deterioration in early Alzheimer’s disease; however, the trial did not meet its primary endpoint, efficacy was not proportional to dose, and key conclusions still await Phase 3 validation.
Australia is attracting Taiwanese drug developers with its notification-based system, early-stage trial capacity, and R&D tax incentives, while Taiwan offers a base for Asian operations and late-stage development. This cross-border pathway has taken shape, but its efficiency has yet to be demonstrated through actual collaborations.
The new framework combines a genomic foundation model with language-based reasoning in an effort to shorten the variant interpretation process for rare diseases. Initial test results were published by the development team, but independent, prospective validation is still needed before clinical adoption.
This protein generation model does not design molecules from scratch. Instead, it builds on the scaffolds of natural proteins, adjusting their length and sequence. Cell-based and binding experiments show that some products can still function, while also clearly revealing the functional costs of substantial size reduction.
The refillable intraocular implant continuously releases ranibizumab in an effort to replace monthly injections with refills every 24 weeks. The treatment burden could be reduced, but eligible patients must first have their condition stabilized with anti-VEGF therapy and accept the risks of implantation surgery and ocular complications.
Samples collected from a melanoma patient over eight years allowed researchers to compare cell morphology with more than 6,000 proteins region by region and trace tumor populations that may have contributed to distant metastasis; however, this remains a single case and is still far from becoming a clinical prediction tool.
A Caltech team combined an enzyme sensor with replenishable cofactors and causal machine learning to estimate changes in blood cholesterol and triglycerides from sweat; a 24-person proof of concept showed potential while also exposing key challenges in selectivity and generalization across individuals.
Researchers found pathogenic variants traceable to birth in newborn blood spots from nearly 2,000 people who later developed childhood cancer. The findings demonstrate the potential of genetic screening, but cannot yet show how many false positives or tangible benefits would result from using it for all newborns.
An in vivo genome-wide screen identified P2RY8 and GNAS as two barriers; after both were knocked out, low-dose CAR-T cells produced complete tumor regression in 4 of 6 mice, but the artificial tumor models and non-peer-reviewed data leave a considerable gap before human application.